Xielan Zhao

发表

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Dajun Yang, Y. Zhai, Q. Niu, 2023, Blood.

miR-150 inhibits terminal erythroid proliferation and differentiation

Jing Liu, X. An, Shuming Sun, 2015, Oncotarget.

Chidamide inhibits cell glycolysis in acute myeloid leukemia by decreasing N6-methyladenosine-related GNAS-AS1.

Chang-mei Hu, Xiao-Hua Fu, Cong Chen, 2023, Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences.

Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial.

Haiwen Huang, Lindong Li, K. Zhou, 2024, Annals of hematology.